Stockreport

La Jolla Pharma up 4% on Giapreza for COVID-19 septic shock [Seeking Alpha]

La Jolla Pharmaceutical Company  (LJPC) 
Last la jolla pharmaceutical company earnings: 3/2 08:30 am Check Earnings Report
US:NASDAQ Investor Relations: lajollapharmaceutical.com/investor-relations
PDF La Jolla Pharmaceutical (NASDAQ:LJPC4%announcementThe FDA approved Giapreza in December 2017 for adults with septic shock or other distributive shock. [Read more]